Table 5: Investigator opinion of efficacy and tolerance on barnidipine at the end of the study visit (Visit 3).
| –
|
Monotherapy |
Combination Therapy |
| –
|
≤55 years |
>55 years |
≤55 years |
>55 years |
| Efficacy, n (%) |
|
|
|
|
|
|
|
|
| Very Good |
1,238 |
(53.6%) |
2,039 |
(51.5%) |
583 |
(43.4%) |
2,309 |
(43.4%) |
| Good |
911 |
(39.5%) |
1,678 |
(42.3%) |
619 |
(46.1%) |
2,508 |
(47.1%) |
| Moderate |
135 |
(5.9%) |
207 |
(5.2%) |
125 |
(9.3%) |
446 |
(8.4%) |
| Not Good |
25 |
(1.1%) |
39 |
(1.0%) |
15 |
(1.1%) |
59 |
(1.1%) |
| Tolerance n (%) |
|
|
|
|
|
|
|
|
| Very Good |
1,402 |
(62.1%) |
2,353 |
(61.1%) |
659 |
(54.2%) |
2,672 |
(54.7%) |
| Good |
747 |
(33.1%) |
1,266 |
(32.9%) |
478 |
(39.3%) |
1,854 |
(37.9%) |
| Moderate |
64 |
(2.8%) |
139 |
(3.6%) |
46 |
(3.8%) |
232 |
(4.8%) |
| Not Good |
43 |
(1.9%) |
90 |
(2.3%) |
33 |
(2.7%) |
130 |
(2.7%) |